Depicting Medullary Thyroid Cancer Recurrence: The Past and the Future of Nuclear Medicine Imaging

CITEDBY Reports

  1. Daniel C. McFarland, Rajan P. Dang, Brett A. Miles, Krzysztof Misiukiewicz, . Four Difficult Thyroid Cancer Cases: Incorporating Medical Therapies. Seminars in Oncology, 2015; 42(6): e83.
    Crossref
  2. E. Grande, J. Santamaría Sandi, J. Capdevila, E. Navarro González, C. Zafón Llopis, T. Ramón y Cajal Asensio, J. M. Gómez Sáez, P. Jiménez-Fonseca, G. Riesco-Eizaguirre, J. C. Galofré, . Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI). Clinical and Translational Oncology, 2016; 18(8): 769.
    Crossref
  3. Giorgio Treglia, Cumali Aktolun, Arturo Chiti, Savvas Frangos, Luca Giovanella, Martha Hoffmann, Ioannis Iakovou, Jasna Mihailovic, Bernd J. Krause, Werner Langsteger, Frederik A. Verburg, Markus Luster, . The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2016; 43(8): 1486.
    Crossref